Conclusion
neutropenia, febrile neutropenia, breast cancer
NEUTROPENIA, FEBRILE NEUTROPENIA, BREAST CANCER
Efbemalenograstim alfa is effective and safe for significantly decreasing the duration of severe neutropenia and the incidence of febrile neutropenia in breast cancer patients who are receiving TA chemotherapy.Trial registration.NCT02872103, August 19, 2016.